The University of Southampton
University of Southampton Institutional Repository

Characteristics associated with anti-osteoporosis medication use. Data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort

Characteristics associated with anti-osteoporosis medication use. Data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort
Characteristics associated with anti-osteoporosis medication use. Data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort
Introduction: Many women at risk of fracture do not receive anti-osteoporosis medication (AOM), while others may be receiving unnecessary treatment.
Purpose: To examine the characteristics associated with AOMuse among women at low and high risks of fracture.
Methods: The Global Longitudinal Study of Osteoporosis in Women (GLOW) is a prospective cohort study in which data were collected, via self-administered questionnaires, from 60,393 non-institutionalized women aged ?55 years in 10 countries between October 1, 2006 and April 30, 2008. This is a cross-sectional analysis of baseline USA data, in which women were classified as having low fracture risk (b65 years; no FRAX risk factors) or high fracture risk (?65 years; prior fracture or ?2 other FRAX risk factors).
Results: Of 27,957 women, 3013 were at low risk of fracture and 3699 were at high risk. Only 35.7% of high-risk women reported AOM treatment, rising to 39.5% for those with self-reported osteopenia and 65.4% for those with self-reported osteoporosis. Conversely, 13.4% of low-risk women reported AOM, rising to 28.7% for osteopenia and 62.4% for osteoporosis. Characteristics associated with significantly higher AOM treatment rates among low- and high-risk women were: osteoporosis (odds ratios 75.3 and 18.1, respectively), osteopenia(17.9 and 6.3), concern about osteoporosis (2.0 and 1.8), higher perceived risk of fracture (2.3 and 1.6), and higher vitality score (1.7 and 1.6).
Conclusion: Use of AOM is frequently inconsistent with published guidelines in both high- and low-risk women.
Characteristics other than FRAX fracture risk appear to influence this use, particularly the presence of
self-reported osteoporosis.
anti-osteoporosis medication, fracture risk, postmenopausal osteoporosis, women
8756-3282
975-980
Guggina, Pamela
4adb6b29-d3a9-4657-baba-5801e2e5d978
Flahive, Julie
2c67ee4d-eea6-4752-8790-922db07731f6
Hooven, Frederick H.
75487234-9de4-4d47-a837-b72662e751ea
Watts, Nelson B.
5c0d14e9-020d-4e1f-802a-163636c5f0ea
Siris, Ethel S.
cc6622ff-fdce-4834-8edf-b9229094f755
Silverman, Stuart
b3ed983a-c9f6-4029-babe-d5d9dce72375
Roux, Christian
1f852839-8036-423f-ade1-a003d42271fa
Pfeilschifter, Johannes
668ca581-77d4-4cfd-8621-ce542183b90e
Greenspan, Susan L.
bca80638-bd85-4682-8012-037c880dfd06
Díez-Pérez, Adolfo
ab9a2208-530c-4f62-b8df-5a6bbf4b6ef6
Cooper, C.
e05f5612-b493-4273-9b71-9e0ce32bdad6
Compston, Juliet E.
1038f0cb-dd36-49e5-8609-9091266faf67
Chapurlat, Roland
d9410f8c-4e4a-465b-8fb6-67efaadaad4c
Boonen, Steven
fbfd999d-e425-406c-b66e-ca1b8150497b
Adachi, Jonathan D.
b332030f-9df9-4fb8-8547-7192a37b2522
Anderson, Frederick A.
46c5965f-b6d7-4682-8435-ec8b085d2ed9
Gehlbach, Stephen
eea0d9ea-2897-46a2-84b9-57dc6dc7824d
Guggina, Pamela
4adb6b29-d3a9-4657-baba-5801e2e5d978
Flahive, Julie
2c67ee4d-eea6-4752-8790-922db07731f6
Hooven, Frederick H.
75487234-9de4-4d47-a837-b72662e751ea
Watts, Nelson B.
5c0d14e9-020d-4e1f-802a-163636c5f0ea
Siris, Ethel S.
cc6622ff-fdce-4834-8edf-b9229094f755
Silverman, Stuart
b3ed983a-c9f6-4029-babe-d5d9dce72375
Roux, Christian
1f852839-8036-423f-ade1-a003d42271fa
Pfeilschifter, Johannes
668ca581-77d4-4cfd-8621-ce542183b90e
Greenspan, Susan L.
bca80638-bd85-4682-8012-037c880dfd06
Díez-Pérez, Adolfo
ab9a2208-530c-4f62-b8df-5a6bbf4b6ef6
Cooper, C.
e05f5612-b493-4273-9b71-9e0ce32bdad6
Compston, Juliet E.
1038f0cb-dd36-49e5-8609-9091266faf67
Chapurlat, Roland
d9410f8c-4e4a-465b-8fb6-67efaadaad4c
Boonen, Steven
fbfd999d-e425-406c-b66e-ca1b8150497b
Adachi, Jonathan D.
b332030f-9df9-4fb8-8547-7192a37b2522
Anderson, Frederick A.
46c5965f-b6d7-4682-8435-ec8b085d2ed9
Gehlbach, Stephen
eea0d9ea-2897-46a2-84b9-57dc6dc7824d

Guggina, Pamela, Flahive, Julie, Hooven, Frederick H., Watts, Nelson B., Siris, Ethel S., Silverman, Stuart, Roux, Christian, Pfeilschifter, Johannes, Greenspan, Susan L., Díez-Pérez, Adolfo, Cooper, C., Compston, Juliet E., Chapurlat, Roland, Boonen, Steven, Adachi, Jonathan D., Anderson, Frederick A. and Gehlbach, Stephen (2012) Characteristics associated with anti-osteoporosis medication use. Data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort. Bone, 51 (6), 975-980. (doi:10.1016/j.bone.2012.08.130,). (PMID:22964142)

Record type: Article

Abstract

Introduction: Many women at risk of fracture do not receive anti-osteoporosis medication (AOM), while others may be receiving unnecessary treatment.
Purpose: To examine the characteristics associated with AOMuse among women at low and high risks of fracture.
Methods: The Global Longitudinal Study of Osteoporosis in Women (GLOW) is a prospective cohort study in which data were collected, via self-administered questionnaires, from 60,393 non-institutionalized women aged ?55 years in 10 countries between October 1, 2006 and April 30, 2008. This is a cross-sectional analysis of baseline USA data, in which women were classified as having low fracture risk (b65 years; no FRAX risk factors) or high fracture risk (?65 years; prior fracture or ?2 other FRAX risk factors).
Results: Of 27,957 women, 3013 were at low risk of fracture and 3699 were at high risk. Only 35.7% of high-risk women reported AOM treatment, rising to 39.5% for those with self-reported osteopenia and 65.4% for those with self-reported osteoporosis. Conversely, 13.4% of low-risk women reported AOM, rising to 28.7% for osteopenia and 62.4% for osteoporosis. Characteristics associated with significantly higher AOM treatment rates among low- and high-risk women were: osteoporosis (odds ratios 75.3 and 18.1, respectively), osteopenia(17.9 and 6.3), concern about osteoporosis (2.0 and 1.8), higher perceived risk of fracture (2.3 and 1.6), and higher vitality score (1.7 and 1.6).
Conclusion: Use of AOM is frequently inconsistent with published guidelines in both high- and low-risk women.
Characteristics other than FRAX fracture risk appear to influence this use, particularly the presence of
self-reported osteoporosis.

This record has no associated files available for download.

More information

Published date: December 2012
Keywords: anti-osteoporosis medication, fracture risk, postmenopausal osteoporosis, women
Organisations: Faculty of Health Sciences

Identifiers

Local EPrints ID: 346783
URI: http://eprints.soton.ac.uk/id/eprint/346783
ISSN: 8756-3282
PURE UUID: ecef822e-6151-4855-a374-69d52f5368f9
ORCID for C. Cooper: ORCID iD orcid.org/0000-0003-3510-0709

Catalogue record

Date deposited: 09 Jan 2013 12:17
Last modified: 18 Mar 2024 02:45

Export record

Altmetrics

Contributors

Author: Pamela Guggina
Author: Julie Flahive
Author: Frederick H. Hooven
Author: Nelson B. Watts
Author: Ethel S. Siris
Author: Stuart Silverman
Author: Christian Roux
Author: Johannes Pfeilschifter
Author: Susan L. Greenspan
Author: Adolfo Díez-Pérez
Author: C. Cooper ORCID iD
Author: Juliet E. Compston
Author: Roland Chapurlat
Author: Steven Boonen
Author: Jonathan D. Adachi
Author: Frederick A. Anderson
Author: Stephen Gehlbach

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×